FDA approves Moderna's mRNA flu vaccine after initial pushback - CBS News
• The FDA has approved Moderna's mFLUSIVA, the first seasonal influenza vaccine utilizing mRNA technology to receive official authorization. • The vaccine is specifically approved for use in adults aged 50 and older, marking a significant milestone for the drugmaker's mRNA platform. • This approval is critical as it demonstrates the potential for mRNA technology to address broader public health challenges beyond COVID-19.
Read story



